目的:探讨 EZH2 在非小细胞肺癌细胞系及临床病理组织中的表达及意义。 方法:利用 RT-PCR 方 法及免疫组织化学染色方法,检测14 株人非小细胞肺癌细胞及84 例早期非小细胞肺癌病理组织中EZH2 表达, 并分析 EZH2 表达与病理组织类型和临床病理特征的相关性。 结果:80% 的非小细胞肺癌细胞株中 EZH2 mRNA 较正常肺组织呈高表达;84 例非小细胞肺癌组织中EZH2 蛋白呈高表达者55 例(占65. 5%),呈不表达者 29 例(占34. 5%);Kaplan-Meier 和Log-rank 分析结果显示EZH2 高表达病人的中位生存期显著短于EZH2 不表 达病人,P 值= 0. 027,具有统计学意义。 结论:EZH2 异常表达可能是促进非小细胞肺癌的发生的重要因素之 一,EZH2 表达可作为非小细胞肺癌预后判断的潜在分子标记物。 同时开展 EZH2 研究可为肺癌的个体化治疗 提供新的前景。

to elucidate the role of EZH2 in non-small cell lung cancer(NSCLC)by in鄄 vestigating both clinical samples and cell lines. Methods:We performed RT-PCR and an immunohisto鄄 chemical analysis of EZH2 expression in 14 NSCLC cell lines and to investigate the association of its expression level with clinic pathological variables in early stage of 84 NSCLC tissues. Results:EZH2 mRNA was increased in 80%NSCLC cell lines compared with normal human lung tissue. The immuno鄄 histochemical analysis classified NSCLC samples( n = 84) into a negative EZH2 expression group( n = 29;34. 5%)and a positive EZH2 expression group(n = 55;65. 5%). Kaplan-Meier survival analysis and log - rank test demonstrated that patients whose samples were classified into the positive EZH2 expression group had a significantly shorter overall survival than no EZH2 expression( P = 0. 027).Conclusions:Abnormal expression of EZH2 gene is one of key molecules to promote progression of NSCLC. EZH2 is a novel predictive marker of cancer progression. Studies on EZH2 should provide a novel perspective on personalized cancer therapies.

R734. 2